TRAW · Traws Pharma, Inc.
$0.51
-0.01 (-2.00%)
At close · Jul 28
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$7.77M
Shares
15.15M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Iain D. Dukes | CEO | $1,401,924 |
| Nikolay Savchuk | COO | $734,810 |
| Werner Cautreels | CEO | $353,897 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Werner Cautreels | CEO | $647,582 |
| Victor Moyo | Chief Medical Officer, Oncology | $478,436 |
| Steven M. Fruchtman | CEO | $410,000 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Steven M. Fruchtman | CEO | $1,106,747 |
| Mark P. Guerin | CFO | $745,518 |
| Victor Moyo | Chief Medical Officer, Oncology | $404,678 |
| Werner Cautreels | CEO | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Steven M. Fruchtman | CEO | $1,326,782 |
| Mark P. Guerin | CFO | $844,699 |
| Mark S. Gelder | Chief Medical Officer | $677,638 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Steven M. Fruchtman | CEO | $2,674,213 |
| Mark P. Guerin | CFO | $1,299,520 |
| Abraham N. Oler | General Counsel | $1,093,291 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Steven M. Fruchtman | CEO | $1,031,823 |
| Mark P. Guerin | CFO | $622,109 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Ramesh Kumar | CEO | $1,207,526 |
| Steven M. Fruchtman | CEO | $772,513 |
| Manoj Maniar | Senior Vice President, Product Development | $576,058 |
| Richard C. Woodman | Chief Medical Officer and Senior Vice President, Research and Development | $425,312 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Ramesh Kumar | CEO | $1,174,535 |
| Steven M. Fruchtman | CEO | $691,046 |
| Manoj Maniar | Senior Vice President, Product Development | $676,191 |